Table 4.

FDA approvals of BRAF plus MEK inhibitors in nonmelanoma cancers.

Drug/Combination	Nonmelanoma indications (Date of FDA approval)
Dabrafenib plus trametinib	Metastatic NSCLC with BRAF V600E mutation (6/22/2017)
	Locally advanced or metastatic anaplastic thyroid cancer with BRAF V600E mutation and with no satisfactory locoregional treatment options (5/4/2018)
Vemurafenib alone	Treatment of patients with Erdheim-Chester disease with BRAF V600 mutation (11/6/2017)
Vemurafenib plus cobimetinib	No nonmelanoma indication
Encorafenib	In combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation (4/9/2020)
Encorafenib plus binimetinib	No nonmelanoma indication